Zacks Research Analysts Increase Earnings Estimates for DYAI

Dyadic International Inc. (NASDAQ:DYAI) – Investment analysts at Zacks Research upped their FY2026 earnings per share (EPS) estimates for shares of Dyadic International in a report issued on Wednesday, May 20th. Zacks Research analyst J. Vandermosten now expects that the biotechnology company will earn $0.13 per share for the year, up from their previous forecast of ($0.12). The consensus estimate for Dyadic International’s current full-year earnings is ($0.12) per share. Zacks Research also issued estimates for Dyadic International’s FY2027 earnings at ($0.08) EPS.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $1.11 million for the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative net margin of 192.40% and a negative return on equity of 1,005.45%.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Dyadic International currently has a consensus rating of “Hold” and an average target price of $3.00.

Dyadic International Price Performance

NASDAQ DYAI opened at $0.74 on Friday. The business’s fifty day moving average price is $0.81 and its 200-day moving average price is $0.87. The stock has a market capitalization of $26.97 million, a price-to-earnings ratio of -3.22 and a beta of 1.18. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.42 and a quick ratio of 2.42. Dyadic International has a 1-year low of $0.65 and a 1-year high of $1.35.

Institutional Investors Weigh In On Dyadic International

A number of institutional investors have recently bought and sold shares of DYAI. Bank of America Corp DE increased its stake in Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares in the last quarter. Perkins Capital Management Inc. increased its stake in Dyadic International by 627.4% in the 3rd quarter. Perkins Capital Management Inc. now owns 348,050 shares of the biotechnology company’s stock worth $411,000 after buying an additional 300,200 shares in the last quarter. Truist Financial Corp increased its stake in Dyadic International by 30.5% in the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock worth $385,000 after buying an additional 76,200 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Dyadic International in the 3rd quarter worth $190,000. Finally, Marathon Capital Management purchased a new stake in Dyadic International in the 3rd quarter worth $41,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.